Abstract
Rationale Poor outcomes are well documented to be associated with inner city children with asthma. Our aim was to determine if therapy via Diskus (fluticasone/salmeterol [Advair 100 or 250]) inhaled twice daily would reduce emergency department (ED) visits, hospitalizations (HOSP), and HOSP days. Methods For this pilot study, enrollment criteria were parent reported ≥5 ED visits in the last 2 years, ≥3 ED visits in the last year, or ≥2 HOSP for asthma in the last 2 years. Study patients were evaluated over 12 months, and served as their own controls; a separate control group of TennCare children not receiving Advair (but all prescribed inhaled corticosteroids) was included. ED visits and HOSP were assessed via childrens' hospital medical records. Results Study patients (n=41; 31M, 10F, age range 8-17) had a mean 24% decrease in ED visits, which was significant (p=0.02) compared to control patients (n=40; 27M, 13F, age range 8-17). Both groups had significant reductions in HOSP and HOSP days. Conclusion Results of this pilot study suggest that twice daily therapy with Advair Diskus is associated with reduced ED visits in inner city children with asthma enrolled in TennCare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
